CN100437109C - 一种治疗肿瘤的注射液的质量控制方法 - Google Patents
一种治疗肿瘤的注射液的质量控制方法 Download PDFInfo
- Publication number
- CN100437109C CN100437109C CNB2005100907664A CN200510090766A CN100437109C CN 100437109 C CN100437109 C CN 100437109C CN B2005100907664 A CNB2005100907664 A CN B2005100907664A CN 200510090766 A CN200510090766 A CN 200510090766A CN 100437109 C CN100437109 C CN 100437109C
- Authority
- CN
- China
- Prior art keywords
- peak
- mobile phase
- volume ratio
- peaks
- parenteral solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 239000007924 injection Substances 0.000 title claims abstract description 27
- 238000002347 injection Methods 0.000 title claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 title abstract description 42
- 239000000047 product Substances 0.000 claims abstract description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 123
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 108
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 108
- 239000000243 solution Substances 0.000 claims description 106
- 238000012360 testing method Methods 0.000 claims description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 239000000543 intermediate Substances 0.000 claims description 38
- 239000013558 reference substance Substances 0.000 claims description 37
- 238000012546 transfer Methods 0.000 claims description 37
- 239000006071 cream Substances 0.000 claims description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 239000000706 filtrate Substances 0.000 claims description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 29
- NYGZYUAVZPIKBZ-BDJLRTHQSA-N Kushenin Natural products O(C)c1c(O)cc2O[C@H]3[C@@H](c2c1)COc1c3ccc(O)c1 NYGZYUAVZPIKBZ-BDJLRTHQSA-N 0.000 claims description 26
- NYGZYUAVZPIKBZ-UHFFFAOYSA-N Lespedezol D1 Natural products C1OC2=CC(O)=CC=C2C2C1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-UHFFFAOYSA-N 0.000 claims description 26
- NYGZYUAVZPIKBZ-ZBEGNZNMSA-N lespedezol D1 Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-ZBEGNZNMSA-N 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 25
- 229940089161 ginsenoside Drugs 0.000 claims description 25
- 229930182494 ginsenoside Natural products 0.000 claims description 25
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 24
- 230000014759 maintenance of location Effects 0.000 claims description 24
- 239000009636 Huang Qi Substances 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000005303 weighing Methods 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 18
- 238000000967 suction filtration Methods 0.000 claims description 18
- 238000003908 quality control method Methods 0.000 claims description 17
- 239000000796 flavoring agent Substances 0.000 claims description 16
- 235000019634 flavors Nutrition 0.000 claims description 16
- 238000005057 refrigeration Methods 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 15
- 238000004659 sterilization and disinfection Methods 0.000 claims description 15
- 239000000945 filler Substances 0.000 claims description 13
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 13
- 239000000377 silicon dioxide Substances 0.000 claims description 13
- 238000011003 system suitability test Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 239000003610 charcoal Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 235000014347 soups Nutrition 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 7
- 239000012088 reference solution Substances 0.000 claims description 7
- 238000005374 membrane filtration Methods 0.000 claims description 3
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 abstract description 13
- 229930015582 oxymatrine Natural products 0.000 abstract description 13
- 239000013067 intermediate product Substances 0.000 abstract description 2
- 241000208340 Araliaceae Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 description 50
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 50
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 50
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 239000002504 physiological saline solution Substances 0.000 description 23
- 206010039491 Sarcoma Diseases 0.000 description 19
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 18
- 238000002512 chemotherapy Methods 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 238000001959 radiotherapy Methods 0.000 description 16
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 108010006464 Hemolysin Proteins Proteins 0.000 description 7
- 239000003228 hemolysin Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 4
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000000292 leukogenic effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 3
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 241000238370 Sepia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010812 external standard method Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000000610 leukopenic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930014456 matrine Natural products 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
批次 | 总峰面积 | 非共有峰面积 | 峰面积比(%) |
1 | 3353.734 | 94.253 | 2.810 |
2 | 3431.465 | 0.000 | 0.000 |
3 | 3208.382 | 53.152 | 1.657 |
4 | 2937.120 | 45.418 | 1.546 |
5 | 3190.165 | 150.871 | 4.729 |
6 | 3271.051 | 47.300 | 1.446 |
7 | 1946.490 | 51.811 | 2.662 |
8 | 3736.125 | 177.700 | 4.756 |
9 | 3199.940 | 0.000 | 0.000 |
10 | 3124.516 | 103.797 | 3.322 |
批次 | 总峰面积 | 非共有峰面积 | 峰面积比(%) |
1 | 3402.774 | 165.141 | 4.853 |
2 | 3454.905 | 145.458 | 4.210 |
3 | 4585.477 | 220.35 | 4.805 |
4 | 3259.54 | 127.746 | 3.919 |
5 | 3311.036 | 165.49 | 4.998 |
6 | 3252.675 | 153.824 | 4.729 |
7 | 2990.128 | 116.488 | 3.896 |
8 | 2875.918 | 121.638 | 4.230 |
9 | 2778.91 | 123.438 | 4.442 |
10 | 2797.493 | 125.597 | 4.490 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100907664A CN100437109C (zh) | 2005-08-16 | 2005-08-16 | 一种治疗肿瘤的注射液的质量控制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100907664A CN100437109C (zh) | 2005-08-16 | 2005-08-16 | 一种治疗肿瘤的注射液的质量控制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1792367A CN1792367A (zh) | 2006-06-28 |
CN100437109C true CN100437109C (zh) | 2008-11-26 |
Family
ID=36804140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100907664A Active CN100437109C (zh) | 2005-08-16 | 2005-08-16 | 一种治疗肿瘤的注射液的质量控制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100437109C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269113B (zh) * | 2008-05-09 | 2012-08-29 | 李彦群 | 一种治疗肿瘤的药物组合物的质量检测方法 |
CN102160868B (zh) * | 2010-11-17 | 2013-03-20 | 安徽医科大学第一附属医院 | 黄芪皂苷ⅳ在制备抗肝癌药物中的应用 |
CN102288717A (zh) * | 2011-05-16 | 2011-12-21 | 王志敏 | 一种治疗或辅助治疗肿瘤疾病的制剂中黄芪的检测方法 |
CN103105371B (zh) * | 2011-11-10 | 2015-03-18 | 长白山制药股份有限公司 | 一种药物组合物注射液的质量检测方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1504218A (zh) * | 2002-11-29 | 2004-06-16 | 李彦群 | 一种治疗肿瘤的药物组合物及其制备方法 |
-
2005
- 2005-08-16 CN CNB2005100907664A patent/CN100437109C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1504218A (zh) * | 2002-11-29 | 2004-06-16 | 李彦群 | 一种治疗肿瘤的药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1792367A (zh) | 2006-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106501434B (zh) | 一种双和汤标准汤的hplc指纹图谱测定方法 | |
CN109400741B (zh) | 一种灵芝孢子多糖的分离纯化方法 | |
CN102977114B (zh) | 桑黄中单体成分-纤孔菌素a及其制备方法和应用 | |
CN101904893B (zh) | 当归补血胶囊的制备方法 | |
CN105859903A (zh) | 一种北沙参多糖及其制备方法和应用 | |
CN105758949B (zh) | 基于量效色卡的气滞胃痛颗粒促胃肠动力质量控制方法 | |
CN100437109C (zh) | 一种治疗肿瘤的注射液的质量控制方法 | |
CN103169737B (zh) | 樟芝子实体与破壁灵芝孢子粉的组合物及其在免疫调节中的应用 | |
CN101239094B (zh) | 一种抗肿瘤辅助用药的有效部位组合物及其制备方法和应用 | |
CN104013636A (zh) | 瓦草五环三萜皂苷类化合物抗肿瘤的药物用途 | |
CN100522184C (zh) | 具有抗肿瘤和抗毒活性的提取物 | |
CN103073650A (zh) | 红芪多糖4及其有效成分的制备和应用 | |
CN100361681C (zh) | 治疗血小板减少、贫血的药物及制备方法和质量控制方法 | |
CN1977885A (zh) | 一种抗肝炎药物组合物 | |
CN101391070B (zh) | 一种具有抗癌作用的中药组合物的检测方法 | |
CN100441190C (zh) | 用于治疗癌症之皂甙或皂甙配基组合物 | |
CN109354629A (zh) | 一种中性三七多糖的提取纯化方法及应用 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN101822709B (zh) | 当归、红芪超滤膜提取物在制备用于抗辐射药物中的应用 | |
CN1954838B (zh) | 一种抗肿瘤的药物组合物 | |
CN106389764A (zh) | 一种中药制剂及其制备与应用 | |
CN1961894B (zh) | 一种新的复方药物组合物及其制备方法和用途 | |
CN105535050A (zh) | 一种当归抗肿瘤药物 | |
CN102697800B (zh) | 繁缕多糖组合物及其在制备抗病毒药物中的应用 | |
CN103120718B (zh) | 一种治疗慢性肝炎、肝硬化的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHANGBAISHAN PHARMACY CO., LTD. Free format text: FORMER OWNER: LI YANQUN Effective date: 20090612 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090612 Address after: No. 43 Changan Road, democratic Street, Jilin, Jiaohe Patentee after: CHANGBAISHAN PHARMACEUTICAL Co.,Ltd. Address before: No. 103, Shenzhen street, hi tech Zone, Jilin, Jilin Patentee before: Li Yanqun |
|
TR01 | Transfer of patent right |
Effective date of registration: 20191218 Address after: 132000 3-1-17, purple garden, camp, Jilin, Jilin Patentee after: Li Dongxuan Address before: 43 No. 132500 Changan Road, democratic Street, Jilin, Jiaohe Patentee before: CHANGBAISHAN PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221123 Address after: 132500 No.43, West Chang'an Road, Minzhu street, Jiaohe City, Jilin Province Patentee after: CHANGBAISHAN PHARMACEUTICAL Co.,Ltd. Address before: 132000 no.3-1-17 Ziguang garden, Chuanying District, Jilin City, Jilin Province Patentee before: Li Dongxuan |
|
TR01 | Transfer of patent right |